Humoral immunity against sars-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech
e202110141
Keywords:
Coronavirus infection, Vaccines, Humoral immunity, ParameterAbstract
Background: Workers and residents of care facilities for elder people/people with disabilities were particularly hit by the COVID-19 pandemic. Workers from these centres were included as a priority group for vaccination against Sars-CoV-2.The Family Ministry of Castilla y León realized a seroprevalence survey measuring the humoral immunity of its workers after the vaccination against Sars-CoV-2.
Methods: In February and March 2021, IgM/IgG antibodies were measured in 7 social health care centers in a total of 1,085 workers at least 15 days after completing the vaccination with the BNT162b2 vaccine from Pfizer/BioNtech. Using the ELISA technique for anti-nucleocapsid (N) IgM and CLIA S-RBD SARS-CoV-2 for anti-spicule (S) IgG, titers were compared between vaccinated with cero, one or two doses, and differentiating in these subgroups between having passed or not COVID-19. Means and percentages were compared using Student’s t and Chi2 (EPIDAT 3.1).
Results: Among the 1,085 workers studied, there were 54 workers with a single dose of vaccine, of which 51 (94%) had a positive IgG (average titers of 459 AU/mL), 951 workers with 2 doses, of which 949 (99.8%) showed positive IgG (mean titers of 677 AU/mL), and 80 unvaccinated workers, of which 51 (64%) had positve IgG (mean titers of 49 AU/mL). 7 cases of COVID-19 were notified at least 15 days after full vaccination. The titers were significantly higher if COVID-19 had been passed in the group vaccinated with 1 and 2 doses (259 vs 894 and 601 vs 1,085 AU/mL respectively, p<0.05), but not in the unvaccinated group (53 vs 34 AU/mL, p>0.05).
Conclusions: 99.8% of social health workers who received 2 doses of the BNT162b2 vaccine from Pfizer/BioNtech, and 94% of those who received 1 single dose, presented humoral immunity with high IgG titers, with high clinical effectiveness expressed in the absence of cases. 64% of unvaccinated workers presented humoral immunity. The history of having passed COVID-19 produces an important booster effect both after one and after two doses of vaccine. Measurement of humoral immunity against Sars-CoV-2 could be considered as a parameter for sufficient immunity.
Downloads
References
Estrategia de vacunación frente a COVID-19 en España. Grupo de Trabajo Técnico de Vacunación COVID-19, de la Ponencia de Programa y Registro de Vacunaciones. 2 de diciembre 2020 y actualizaciones ulteriores. https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/vacunaCovid19.htm
Análisis de la efectividad y el impacto de la vacunación frente a COVID-19 en residentes de centros de mayores en España. Grupo de Trabajo de Efectividad Vacunación COVID-19. 25/04/2021. https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/Efectividad_vacunaCOVID-19.htm. Informe del grupo de análisis científico de coronavirus del Instituto Carlos III (GACC-ISCIII). Anticuerpos neutralizantes frente a Sars-CoV-2. 02 de julio 2020.
Manual de vacunaciones. Servicio Central de Publicaciones del Gobierno Vasco. 2020. http://www.euskadi.eus/informacion/manual-de-vacunaciones/web01-a2gaixo/es/
Immune responses and immunity to SARS-CoV-2. ECDC. 20 June 2020. https://www.ecdc.europa.eu/en/covid-19/latest-evidence/immune-responses
Informe de grupo de análisis científico de coronavirus del Instituto Carlos III (GACC-ISCIII): Anticuerpos neutralizantes frente a Sars-CoV-2. 02 de julio 2020.
Situación epidemiológica del coronavirus (COVID-19) en Castilla y León. https://analisis.datosabiertos.jcyl.es/pages/coronavirus/
Achiron A, Mandel M,Dreyer-Alster et al. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Therapeutic Advances in Neurological Disorders. April 22, 2021. https://doi.org/10.1177/17562864211012835
European Centre for Disease Prevention and Control. Risk of SARS-CoV-2 transmission from newly-infected individuals with documented previous infection or vaccination. 29 March 2021. ECDC: Stockholm, 2021
Collier DA, Ferreira I, Datir R, Meng B, Bergamaschi L, Elmer A. Age-related heterogeneity in neutralising antibody responses to SARS-CoV-2 following BNT162b2 vaccination. medRxiv preprint; doi: https://doi.org/10.1101/2021.02.03.21251054
Lombardi A, Consonni D, Oggioni M, Bono P, Renteria SU, Piatti A, Pesatori AC, Castaldi S, Muscatello A, Riboldi L, Ceriotti F, Bandera A, Gori A. SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals. J Infect Public Health. 2021 Aug;14(8):1120-1122. doi: 10.1016/j.jiph.2021.07.005. Epub 2021 Jul 17. PMID: 34293641; PMCID: PMC8285930.
Krammer F, Srivastava K, Simon V. Robust spike antibody 1 responses and increased reactogenicity in seropositive individuals after a 2 single dose of SARS-CoV-2 mRNA vaccine. medRxiv preprint; doi: https://doi.org/10.1101/2021.01.29.21250653
Saadat S, Rikhtegaran-Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, Sajadi MM. Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2. Institute of Human Virology, University of Maryland School of Medicine, Baltimore. medRxiv preprint; doi: https://doi.org/10.1101/2021.01.30.21250843
Mattiuzzo et al. Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2
antibody. 2020, WHO EXPERT COMMITTEE
ON BIOLOGICAL STANDARDIZATION. WHO/BS/20. Geneva, 9-10 December 2020. https://www.who.int/publications/m/item/WHO-BS-2020.2403
WHO/BS.2020.2403 Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody. https://www.who.int/publications/m/item/WHO-BS-2020.2403
Garcia-Beltran WF; Lam EC, Astudillo MG, Yang D. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. Volume 184, Issue 2, 21 January 2021, Pages 476-488.e11. https://www.sciencedirect.com/science/article/pii/S0092867420316858
European Centre for Disease Prevention and Control. SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update – 15 February 2021. ECDC: Stockholm; 2021 https://www.ecdc.europa.eu/en/publications-data/covid-19-risk-assessment-variants-vaccine-fourteenth-update-february-2021
Impact and Effectiveness of mRNA BNT162b2 Vaccine Against SARS-CoV-2 Infections and COVID-19 Cases, Hospitalizations, and Deaths Following a Nationwide Vaccination Campaign in Israel: An Observational Study Using National Surveillance Data. Lancet 2021;May 5:[Epub ahead of print].
Amit S, Beni S, Biber A, Grinberg A, Leshem E, Regev-Yochay G. Postvaccination COVID-19 among Healthcare Workers, Israel. Emerg Infect Dis. 2021;27(4):1220-1222. https://doi.org/10.3201/eid2704.210016
Collier DA, Ferreira I, Datir R, Meng B, Bergamaschi L, Elmer A. Age-related heterogeneity in neutralising antibody responses to SARS-CoV-2 following BNT162b2 vaccination. medRxiv preprint; doi: https://doi.org/10.1101/2021.02.03.21251054
Mulligan MJ, Lyke KE, Kitchin N et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020; 586: 589-593
Whitaker H, Elgohari S, Rowe C, Otter A, Brooks T, Linley E, Hayden I, Ribeiro S, Hewson J, Lakhani A, Clarke E, Tsang C, Campbell C, Ramsay ME, Brown K, Amirthalingam G. Impact of COVID-19 Vaccination Program on Seroprevalence in Blood Donors in England, 2021 (March 16, 2021). Available at SSRN: https://ssrn.com/abstract=3803380 or http://dx.doi.org/10.2139/ssrn.3803380
Grupper A, Sharon N, Finn T, Cohen R, Israel M. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis. CJASN April 2021.DOI: https://doi.org/10.2215/CJN.03500321
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Ricardo Casas Fischer
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
